Skip to main content

Advertisement

SpringerLink
Log in

Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Atherosclerosis is an example of an inflammatory disorder. During the acute phase and under inflammatory conditions, high-density lipoprotein (HDL), which is normally anti-inflammatory, can become proinflammatory. Reactive oxygen species generated by several enzyme systems can modify phospholipids and sterols, producing oxidized phospholipids and oxidized sterols that reduce the capacity of HDL to protect against undesirable oxidative modifications of molecules. In animal models of dyslipidemia, diabetes, vascular inflammation, and chronic rejection, it is observed that reducing oxidative and inflammatory pressure will help HDL regain its protective role. One way to accomplish this is through the use of apolipoprotein A-I mimetic peptides, which remove oxidation products from lipoproteins and cell membranes, returning normal structure and function to low-density lipoprotein and HDL. These mimetic peptides markedly reduce atherosclerosis in animal models. Published studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis suggest that they have efficacy in a wide range of inflammatory conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234–1241.

    Article  PubMed  CAS  Google Scholar 

  2. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994, 91:9607–9611.

    Article  PubMed  CAS  Google Scholar 

  3. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.

    Article  PubMed  CAS  Google Scholar 

  4. Tardif JC, Gregoire J, L’Allier PL, et al.: Effect of rHDL on atherosclerosis-safety and efficacy [ERASE] investigators. JAMA 2007, 297:1675–1682.

    Article  PubMed  Google Scholar 

  5. Anantharamaiah GM, Jones JL, Brouillette CG, et al.: Studies of synthetic peptide analogs of amphipathic helix I: structure of peptide/DMPC complexes. J Biol Chem 1985, 260:10248–10255.

    PubMed  CAS  Google Scholar 

  6. Venkatachalapathi YV, Phillips MC, Epand RM, et al.: Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins Structure Function Genet 1993, 15:349–359.

    Article  CAS  Google Scholar 

  7. Yancey PG, Bielicki JK, Lund-Katz S, et al.: Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995, 34:7955–7965.

    Article  PubMed  CAS  Google Scholar 

  8. Datta G, Chaddha M, Hama S, et al.: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096–1104.

    PubMed  CAS  Google Scholar 

  9. Fogelman AM: When pouring water on the fire makes it burn brighter. Cell Metab 2005, 2:6–8.

    Article  PubMed  CAS  Google Scholar 

  10. Wu BJ, Kathir K, Witting PK, et al.: Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006, 203:1117–1127.

    Article  PubMed  CAS  Google Scholar 

  11. Stocker R, Perrella MA: Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation 2006, 114:2178–2189.

    Article  PubMed  CAS  Google Scholar 

  12. Gharavi NM, Gargalovic PS, Chang I, et al.: High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler Thromb Vasc Biol 2007, 27:1346–1353.

    Article  PubMed  CAS  Google Scholar 

  13. Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290–292.

    Article  PubMed  CAS  Google Scholar 

  14. Navab M, Anantharamaiah GM, Reddy ST, et al.: Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215–3220.

    Article  PubMed  CAS  Google Scholar 

  15. Li X, Chyu KY, Faria JR, et al.: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004, 110:1701–1705.

    Article  PubMed  CAS  Google Scholar 

  16. Navab M, Anantharamaiah GM, Hama S, et al.: D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1426–1432.

    Article  PubMed  CAS  Google Scholar 

  17. Navab M, Anantharamaiah GM, Reddy ST, et al.: An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1932–1937.

    Article  PubMed  CAS  Google Scholar 

  18. Navab M, Anantharamaiah GM, Reddy ST, et al.: Oral small peptides render HDL anti-inflammatory in mice and monkeys and reduce atherosclerosis in apoE null mice. Circ Res 2005, 97:524–532.

    Article  PubMed  CAS  Google Scholar 

  19. Van Lenten BJ, Wagner A, Navab M, Fogelman AM: Circulation 2007 [Epub ahead of print].

  20. Navab M, Anantharamaiah GM, Reddy ST, et al.: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325–1331.

    Article  PubMed  CAS  Google Scholar 

  21. Berliner JA, Watson AD: A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005, 353:9–12.

    Article  PubMed  CAS  Google Scholar 

  22. Gargalovic PS, Imura M, Zhang B, et al.: Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A 2006, 103:12741–12746.

    Article  PubMed  CAS  Google Scholar 

  23. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al.: Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002, 106:1127–1132.

    Article  PubMed  Google Scholar 

  24. Van Lenten BJ, Wagner AC, Navab M, et al.: D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004, 110:3252–3258.

    Article  PubMed  Google Scholar 

  25. Gupta H, Dai L, Datta G, et al.: Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005, 97:236–243.

    Article  PubMed  CAS  Google Scholar 

  26. Buga GM, Frank JS, Mottino GA, et al.: D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res 2006, 47:2148–2160.

    Article  PubMed  CAS  Google Scholar 

  27. Kruger AL, Peterson S, Turkseven S, et al.: D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloghing, and improves vascular reactivity in rat model of diabetes. Circulation 2005, 111:3126–3134.

    Article  PubMed  CAS  Google Scholar 

  28. Peterson SJ, Husney D, Kruger AL, et al.: Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 2007, 322:514–520.

    Article  PubMed  CAS  Google Scholar 

  29. Araujo JA, Meng L, Tward AD, et al.: Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. J Immunol 2003, 171:1572–1580.

    PubMed  CAS  Google Scholar 

  30. Schnickel GT, Hsieh GR, Kachikwu EL, et al.: Cytoprotective gene HO-1 and chronic rejection in heart transplantation. Transplant Proc 2006, 38:3259–3262.

    Article  PubMed  CAS  Google Scholar 

  31. Hsieh GR, Schnickel GT, Garcia C, et al.: Inflammation/oxidation in chronic rejection: apolipoprotein A-I mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007, 84:238–243.

    Article  PubMed  CAS  Google Scholar 

  32. Ou Z, Ou J, Ackerman AW, et al.: L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation 2003, 107:1520–1524.

    Article  PubMed  CAS  Google Scholar 

  33. Ou J, Ou Z, Jones DW, et al.: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337–2341.

    Article  PubMed  CAS  Google Scholar 

  34. Ou J, Wang J, Xu H, et al.: Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double knockout mice on Western diet. Circ Res 2005, 97:1190–1197.

    Article  PubMed  CAS  Google Scholar 

  35. Weihrauch D, Xu H, Shi Y, et al.: Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007, 293:H1432–H1441.

    Article  PubMed  CAS  Google Scholar 

  36. Buga GM, Frank JS, Mottino GA, et al.: D-4F Reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor null mice fed a Western diet. J Lipid Res 2007, [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Room BH-307 CHS, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA, 90095, USA

    Mohamad Navab

Authors
  1. Roger Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Babak Yekta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ladan Vakili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Navid Gharavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohamad Navab
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel Marelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Abbas Ardehali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamad Navab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, R., Yekta, B., Vakili, L. et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 10, 171–176 (2008). https://doi.org/10.1007/s11883-008-0025-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0025-z

Keywords

Search

Navigation